Bernstein analyst Lee Hambright raised the firm’s price target on Johnson & Johnson to $208 from $193 and keeps a Market Perform rating on the shares. After a low point in September 2025, U.S. healthcare stocks have begun to perform better over the past several months, the firm notes. As the market gets more clarity on many of the macro / policy uncertainties that weighed on healthcare stocks during the course of 2025, Bernstein anticipates better days ahead for healthcare stocks in 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson Wins Tariff Relief from Trump in a Drug Pricing Deal
- J&J announces two new U.S. manufacturing facilities
- J&J reaches pact with U.S. government over access to medicines
- Lexeo Therapeutics announces research collab with Johnson & Johnson
- LLY, JNJ, PFE: Big Pharma’s 2025 Comeback Is Bigger Than the Obesity Craze